Fig 1.
Flow diagram of study participants.
Table 1.
Baseline participant characteristics.
Fig 2.
Serum 25-hydroxyvitamin D [25(OH)D] concentrations at baseline, 8 weeks, and 16 weeks.
Response to 16 weeks of monthly supplementation in the form of either placebo (n = 17), 18,000 IU of vitamin D3 (600 IU/day, n = 17), 60,000 IU of vitamin D3 (2,000 IU/day, n = 18), or 120,000 IU of vitamin D3 (4,000 IU/day, n = 18). Values are means ± SD. The P value indicates the test of the dose-response trend. Data represent mean ± SD. *P < 0.05, NS = not significant.
Table 2.
Arterial stiffness measurements at baseline and 16 weeks in overweight African Americans with vitamin D deficiency randomly assigned to 16 weeks of monthly supplementation in the form of either placebo (n = 17), 18,000 IU of vitamin D3 (600 IU/day, n = 17), 60,000 IU of vitamin D3 (2,000 IU/day, n = 18), or 120,000 IU of vitamin D3 (4,000 IU/day, n = 18).
Fig 3.
Effect of vitamin D3 supplementation on arterial stiffness.
Relative changes from baseline in carotid-femoral pulse wave velocity (A) and carotid-radial pulse wave velocity (B) in response to 16 weeks of monthly supplementation in the form of either placebo (n = 17), 18,000 IU of vitamin D3 (600 IU/day, n = 17), 60,000 IU of vitamin D3 (2,000 IU/day, n = 18), or 120,000 IU of vitamin D3 (4,000 IU/day, n = 18). The P-value indicates the test of the dose-response trend. Data represent mean ± SD. *P < 0.05, NS = not significant.